DDR1 Drives Collagen Remodeling and Immune Exclusion: Pan-Cancer Insights and Therapeutic Targeting in Pancreatic Ductal Adenocarcinoma
International Journal of Molecular Sciences · 10.08.2025 · 26 (16) · 7731
DOI: 10.3390/ijms26167731 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.08.2025. Verfasst von Xuan Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmaceutical Sciences, Fudan University,…. Hauptthemen laut MEDLINE: Discoidin Domain Receptor 1, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Collagen. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Macau Science and Technology Development Fund, Macau Science and Technology Development Fund.
Abstract (Originalsprache)
Discoidin domain receptor 1 (DDR1), a collagen-binding receptor tyrosine kinase, plays a key role in extracellular matrix remodeling, tumor progression, and immune evasion. However, DDR1’s comprehensive role across diverse cancers and its therapeutic potential in immune-resistant tumors remain poorly defined. We performed a pan-cancer analysis integrating bulk transcriptomic datasets, single-cell RNA sequencing, and pathway enrichment to evaluate DDR1 expression, genetic alterations, and its associations with immune cell infiltration and clinical outcomes. DDR1 was consistently overexpressed in 21 cancer types, correlating with poor prognosis and reduced immune cell infiltration. Mechanistically, DDR1 promoted collagen remodeling, immune exclusion, and upregulated immunosuppressive pathways. Single-cell analysis in pancreatic ductal adenocarcinoma (PDAC) revealed DDR1-high ductal cells associated with reduced cytotoxic T cell infiltration and increased regulatory T cell populations. Therapeutic blockade of DDR1 in an immunocompetent KPC mouse model of PDAC disrupted collagen architecture, enhanced CD8+ T cell infiltration, and improved responses to chemotherapy, highlighting a direct link between DDR1 inhibition and immune reactivation. These findings establish DDR1 as a key mediator of collagen-driven immune resistance and a promising therapeutic target for overcoming immune exclusion, especially in PDAC and other collagen-rich solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmaceutical Sciences, Fudan University, Shanghai 201100, China.
- School of Pharmacy & Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau SAR, China.
- School of Life Science and Technologies, Tongji University, Shanghai 200065, China.
ORCID-Profile: Xuan Huang, Yi Zhun Zhu, Li Ye
Förderung
- the Macau Science and Technology Development Fund
- Macau Science and Technology Development Fund
Zitieren
APA
Huang, X., Jing, G., Kuerban, K., Fan, J., Yu, M., Yang, S., Chen, W., Huang, L., Ju, D., Zhu, Y. Z., & Ye, L. (2025). DDR1 Drives Collagen Remodeling and Immune Exclusion: Pan-Cancer Insights and Therapeutic Targeting in Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences, 26(16), 7731. https://doi.org/10.3390/ijms26167731
Vancouver
Huang X, Jing G, Kuerban K, Fan J, Yu M, Yang S, et al. DDR1 Drives Collagen Remodeling and Immune Exclusion: Pan-Cancer Insights and Therapeutic Targeting in Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences. 2025;26(16):7731. doi:10.3390/ijms26167731
BibTeX
@article{Huang2025,
author = {Huang, Xuan and Jing, Guangjun and Kuerban, Kudelaidi and Fan, Jiajun and Yu, Mei and Yang, Shanglin and Chen, Wei and Huang, Litao and Ju, Dianwen and Zhu, Yi Zhun and Ye, Li},
title = {DDR1 Drives Collagen Remodeling and Immune Exclusion: Pan-Cancer Insights and Therapeutic Targeting in Pancreatic Ductal Adenocarcinoma},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {16},
pages = {7731},
doi = {10.3390/ijms26167731}
}
EUVIMED